Can-Fite BioPharma Reports H1 2025 Results and Updates

Can-Fite BioPharma Ltd ( (CANF) ) has released its Q2 earnings. Here is a breakdown of the information Can-Fite BioPharma Ltd presented to its investors.

Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small molecule drugs for oncological and inflammatory diseases, with a strong emphasis on targeting the A3 adenosine receptor.

In its latest financial report for the first half of 2025, Can-Fite BioPharma Ltd. announced significant clinical milestones and financial results. The company highlighted progress in its drug development pipeline, particularly with its Namodenoson and Piclidenoson candidates.

Namodenoson, a selective A3 adenosine receptor agonist, reached over 50% enrollment in its Phase 2a study for pancreatic cancer, demonstrating a favorable safety profile. Additionally, the drug received FDA approval for compassionate use, attracting interest from U.S. medical centers. Meanwhile, Piclidenoson showed promising results in a UCLA study for vascular dementia, a condition with no FDA-approved therapies, potentially positioning Can-Fite in a lucrative market.

Financially, Can-Fite reported a decrease in revenues to $0.20 million, attributed to lower advance payments from distribution agreements. Research and development expenses increased due to ongoing studies, while general and administrative expenses rose due to investor relations activities. The company ended the period with a net loss of $4.87 million, reflecting its continued investment in drug development.

Looking ahead, Can-Fite remains committed to advancing its clinical programs and leveraging its platform technology to address significant market opportunities in cancer and inflammatory diseases, as it navigates the challenges of the biotechnology sector.